137 related articles for article (PubMed ID: 35121201)
1. Identification of new potent anticancer derivatives through simplifying the core structure and modification on their 14- hydroxyl group from oridonin.
Liu J; Xie S; Shao X; Xue S; Du P; Wu H; Xu S; Chen ZS; Yang DH; Xu J; Yao H
Eur J Med Chem; 2022 Mar; 231():114155. PubMed ID: 35121201
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of Oridonin Derivatives via Mizoroki-Heck Reaction and Click Chemistry for Cytotoxic Activity.
Hou W; Fan Q; Su L; Xu H
Anticancer Agents Med Chem; 2019; 19(7):935-947. PubMed ID: 30657049
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of novel oridonin analogues as potent anticancer agents.
Shen QK; Chen ZA; Zhang HJ; Li JL; Liu CF; Gong GH; Quan ZS
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):324-333. PubMed ID: 29303372
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, and evaluation of in vitro and in vivo anticancer activity of 14-substituted oridonin analogs: A novel and potent cell cycle arrest and apoptosis inducer through the p53-MDM2 pathway.
Shen QK; Deng H; Wang SB; Tian YS; Quan ZS
Eur J Med Chem; 2019 Jul; 173():15-31. PubMed ID: 30981113
[TBL] [Abstract][Full Text] [Related]
5. Novel anticancer oridonin derivatives possessing a diazen-1-ium-1,2-diolate nitric oxide donor moiety: Design, synthesis, biological evaluation and nitric oxide release studies.
Xu S; Wang G; Lin Y; Zhang Y; Pei L; Yao H; Hu M; Qiu Y; Huang Z; Zhang Y; Xu J
Bioorg Med Chem Lett; 2016 Jun; 26(12):2795-2800. PubMed ID: 27158140
[TBL] [Abstract][Full Text] [Related]
6. A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest through the Mitochondrial Pathway.
Xu S; Yao H; Luo S; Zhang YK; Yang DH; Li D; Wang G; Hu M; Qiu Y; Wu X; Yao H; Xie W; Chen ZS; Xu J
J Med Chem; 2017 Feb; 60(4):1449-1468. PubMed ID: 28165738
[TBL] [Abstract][Full Text] [Related]
7. The conversion of oridonin to spirolactone-type or enmein-type diterpenoid: synthesis and biological evaluation of ent-6,7-seco-oridonin derivatives as novel potential anticancer agents.
Wang L; Li D; Xu S; Cai H; Yao H; Zhang Y; Jiang J; Xu J
Eur J Med Chem; 2012 Jun; 52():242-50. PubMed ID: 22483090
[TBL] [Abstract][Full Text] [Related]
8. Spirolactone-type and enmein-type derivatives as potential anti-cancer agents derived from oridonin.
Ni X; He C; Jia Y; Wu X; Zhou K; Xu S; Xu J; Yao H
Bioorg Med Chem; 2022 Oct; 72():116977. PubMed ID: 36037626
[TBL] [Abstract][Full Text] [Related]
9. Oridonin derivatives as potential anticancer drug candidates triggering apoptosis through mitochondrial pathway in the liver cancer cells.
Luo D; Yi Y; Peng K; Liu T; Yang J; Liu S; Zhao W; Qu X; Yu W; Gu Y; Wan S
Eur J Med Chem; 2019 Sep; 178():365-379. PubMed ID: 31200238
[TBL] [Abstract][Full Text] [Related]
10. Probing the Anticancer Action of Oridonin with Fluorescent Analogues: Visualizing Subcellular Localization to Mitochondria.
Xu S; Luo S; Yao H; Cai H; Miao X; Wu F; Yang DH; Wu X; Xie W; Yao H; Chen ZS; Xu J
J Med Chem; 2016 May; 59(10):5022-34. PubMed ID: 27089099
[TBL] [Abstract][Full Text] [Related]
11. Novel nitrogen-enriched oridonin analogues with thiazole-fused A-ring: protecting group-free synthesis, enhanced anticancer profile, and improved aqueous solubility.
Ding C; Zhang Y; Chen H; Yang Z; Wild C; Chu L; Liu H; Shen Q; Zhou J
J Med Chem; 2013 Jun; 56(12):5048-58. PubMed ID: 23746196
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of novel Jiyuan Oridonin A-1,2,3-triazole-azole derivatives as antiproliferative agents.
Ke Y; Liang JJ; Hou RJ; Li MM; Zhao LF; Wang W; Liu Y; Xie H; Yang RH; Hu TX; Wang JY; Liu HM
Eur J Med Chem; 2018 Sep; 157():1249-1263. PubMed ID: 30193221
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and Cytotoxicity Assessment of Novel 7-O- and 14-O-Derivatives of Glaucocalyxin A.
Liu HC; Qiao LM; Zheng W; Xiang ZB; Chen HS; Yu SC; Zhang DZ; Wang T; Zhang YF; Jin YS
Anticancer Agents Med Chem; 2020; 20(10):1241-1249. PubMed ID: 32116205
[TBL] [Abstract][Full Text] [Related]
14. Identification of a Potent Oridonin Analogue for Treatment of Triple-Negative Breast Cancer.
Yao H; Xie S; Ma X; Liu J; Wu H; Lin A; Yao H; Li D; Xu S; Yang DH; Chen ZS; Xu J
J Med Chem; 2020 Aug; 63(15):8157-8178. PubMed ID: 32610904
[TBL] [Abstract][Full Text] [Related]
15. Effective enmein-type mimics of clinical candidate HAO472: Design, synthesis and biological evaluation.
Hu X; Bai Z; Qiao J; Li H; Xu S; Wang X; Xu Y; Xu J; Hua H; Li D
Eur J Med Chem; 2019 Jun; 171():169-179. PubMed ID: 30921757
[TBL] [Abstract][Full Text] [Related]
16. Enmein-type diterpenoid analogs from natural kaurene-type oridonin: Synthesis and their antitumor biological evaluation.
Li D; Xu S; Cai H; Pei L; Zhang H; Wang L; Yao H; Wu X; Jiang J; Sun Y; Xu J
Eur J Med Chem; 2013 Jun; 64():215-21. PubMed ID: 23644204
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of novel 1-O- and 14-O-derivatives of oridonin as potential anticancer drug candidates.
Xu J; Yang J; Ran Q; Wang L; Liu J; Wang Z; Wu X; Hua W; Yuan S; Zhang L; Shen M; Ding Y
Bioorg Med Chem Lett; 2008 Aug; 18(16):4741-4. PubMed ID: 18644718
[TBL] [Abstract][Full Text] [Related]
18. Hydrogen sulfide donating ent-kaurane and spirolactone-type 6,7-seco-ent-kaurane derivatives: Design, synthesis and antiproliferative properties.
Li H; Gao X; Huang X; Wang X; Xu S; Uchita T; Gao M; Xu J; Hua H; Li D
Eur J Med Chem; 2019 Sep; 178():446-457. PubMed ID: 31202992
[TBL] [Abstract][Full Text] [Related]
19. 6,7-Seco-ent-Kauranoids Derived from Oridonin as Potential Anticancer Agents.
Xu S; Yao H; Hu M; Li D; Zhu Z; Xie W; Yao H; Wu L; Chen ZS; Xu J
J Nat Prod; 2017 Sep; 80(9):2391-2398. PubMed ID: 28901767
[TBL] [Abstract][Full Text] [Related]
20. Oridonin, a Promising ent-Kaurane Diterpenoid Lead Compound.
Li D; Han T; Liao J; Hu X; Xu S; Tian K; Gu X; Cheng K; Li Z; Hua H; Xu J
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27563888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
